cjc+ipa blend vs tesamorelin
updated
cjc+ipa blend (tier A) vs tesamorelin (tier S): what each is, why each got its grade, half-life and source counts side by side.
cjc+ipa blend · tier A
clinic-standard GH-axis pairing. cjc-1295 + ipamorelin. receptor logic first, blend trial evidence still thin.
tier rationale
A-tier reflects receptor-pair logic and component-level pharmacology. Not S-tier because direct fixed-blend outcome trials and long-term safety data are missing. The blend is plausible, widely used, and still less proven than the clinic market makes it sound.
tesamorelin · tier S
the FDA-approved injection that targets visceral fat. the dangerous kind.
tier rationale
different mechanism than GLP-1s. tesa tells your pituitary to pulse growth hormone, which mobilizes visceral fat. clean, targeted, documented. FDA-approved since 2010 for HIV-associated lipodystrophy. long-term cardiovascular safety still uncertain. increasingly used off-label by men 40+ for body recomp. S because drug-tier human trial data exists. narrow indication and high cost keep it niche.
at a glance
| cjc+ipa blend | tesamorelin | |
|---|---|---|
| tier | A | S |
| category | gh / growth | weight loss / gh / growth |
| sources | 19 | 28 |
| claims evaluated | 6 | 8 |
| half-life | CJC-1295: 30 min | ~8-11 minutes |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.